Second-line chemotherapy for advanced gastric cancer
Author Information
Author(s): Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli A M, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G
Primary Institution: Azienda Ospedaliera ‘Ospedale San Salvatore’, Pesaro, Italy
Hypothesis
What clinico-pathologic factors influence survival in patients with advanced gastric cancer receiving second-line chemotherapy?
Conclusion
Certain clinical factors can help identify advanced gastric cancer patients who may benefit from second-line chemotherapy.
Supporting Evidence
- 20-40% of patients with advanced gastric cancer receive second-line chemotherapy.
- Five independent factors were associated with poor overall survival.
- Median survival times were 12.7 months for low-risk, 7.1 months for intermediate-risk, and 3.3 months for high-risk groups.
Takeaway
Some patients with advanced stomach cancer can get a second round of chemotherapy, and doctors can use certain signs to figure out who might do better with it.
Methodology
The study analyzed clinico-pathologic factors in 175 patients who received second-line chemotherapy for advanced gastric cancer.
Potential Biases
Potential publication bias due to the inclusion of small participant numbers in trials.
Limitations
The study is retrospective and lacks data from randomized trials.
Participant Demographics
Median age was 64 years, with 66% male and 23.4% having poor performance status.
Statistical Information
P-Value
P<0.001
Confidence Interval
95% CI, 1.16–2.77
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website